Inhibiting TEM recruitment into tumours by pharmacologically interfering with the CXCL12/CXCR4 axis increased the efficacy of radiation or vascular-disrupting agents in GBM and murine mammary tumours5, 33. The gene discussed is CXCR4; the disease is glioblastoma.